Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Study of Ovarex® (oregovomab) MAb with Front-line Chemotherapy for Ovarian Cancer Treatment
This study is currently recruiting patients.
Sponsored by: | Unither Pharmaceuticals |
---|---|
Information provided by: | Unither Pharmaceuticals |
Purpose
An experimental treatment with OvaRex® MAb-B43.13 (oregovomab), called immunotherapy is being tested in ovarian cancer patients. Immunotherapy causes the body’s defenses to react against cancer cells. The purpose of this research study is to determine if immunotherapy with oregovomab can create an immune response and enable the body to fight the disease and help ovarian cancer patients live longer. Patients with a possible diagnosis of ovarian cancer will be screened for study participation pre-surgery and, if eligible, will receive oregovomab during front-line chemotherapy treatment for ovarian cancer and quarterly for about a year following chemotherapy. Patients who experience disease progression will be discontinued from oregovomab therapy. Patients will also have urine, blood and tissue samples collected to assess the immune response to oregovomab.
Condition | Treatment or Intervention | Phase |
---|---|---|
Ovarian Cancer |
Drug: oregovomab |
Phase II |
MedlinePlus related topics: Ovarian Cancer
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Historical Control, Parallel Assignment
Official Title: An Open-Label, Phase II Study of Ovarex® MAb-B43.13 as an Adjuvant Treatment to Platinum-based Front-line Chemotherapy of Advanced Epithelial Carcinoma of Ovarian, Tubal, or Peritoneal Origin
Expected Total Enrollment: 40
Study start: July 2004
Eligibility
Ages Eligible for Study: up to 80 Years, Genders Eligible for Study: Female
Criteria
Inclusion Criteria:
Exclusion Criteria:
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |